July 2019
Volume 5, Issue 8
This issue features an exclusive interview with National Institute on Aging Director Richard Hodes, MD, and more.
Table of Contents
July 2019 Issue
Illegitimi EPIC Non Carborundum (Don’t Let the EPIC Bastards Grind You Down)
After having served a recent tour of duty caring for patients in the hospital, I was reminded by the hospital’s billing department that I...
July 2019 Issue
New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more
Next ASH Congressional Fellow Is Bound for Capitol Hill
Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the...
Steven Rosenberg Receives Szent-Györgyi Prize, FDA Names Elizabeth Jungman Head of Regulatory Policy, and...
Steven A. Rosenberg Receives Szent-Györgyi Prize
The National Foundation for Cancer Research has awarded Steven A. Rosenberg, MD, PhD, the 2019 Szent-Györgyi Prize for Progress...
July 2019 Issue
Pulling Back the Curtain: Anna Schuh, MD, PhD
In this edition, Anna Schuh, MD, PhD, speaks about her idyllic childhood in the vineyards of Germany’s Moselle Valley and being chased by wildebeest...
The Wisdom of Aging
ASH Clinical News spoke with Richard J. Hodes, MD, director of the National Institute on Aging (NIA) at the National Institutes of Health (NIH),...
July 2019 Issue
How does triple X syndrome interact with Fanconi anemia?
This month, Joanne Kurtzberg, MD, discusses allogeneic hematopoietic cell transplantation in a patient with Fanconi anemia.
And don't forget to check out next month's clinical...
Reader Responses: How does triple X syndrome interact with Fanconi anemia?
Here’s how readers responded to a You Make the Call question about allogeneic hematopoietic cell transplantation in a patient with Fanconi anemia.
Disclaimer: ASH does...
July 2019 Issue
Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients With Blood Cancers
Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...
Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm
Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...
Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL
In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...
TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML
In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
FDA to Close Its Controversial Medical Device Reporting Program
In what is being called a victory for patients and consumers, the U.S. Food and Drug Administration (FDA) said that it is ending its...
FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML
On May 2, 2019, The U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment...
Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma
In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma
The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...
Venetoclax Approved for CLL and SLL
The U.S. Food and Drug Administration (FDA) approved venetoclax, in combination with obinutuzumab, for the treatment of adult patients with chronic lymphocytic leukemia (CLL)...
Scientists Depart MD Anderson and Emory Over Undisclosed Ties to China
Two recent incidents illustrate the growing concern in the U.S. research community that China and other foreign governments have been using visiting scholars to...
July 2019 Issue
New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients
Daratumumab-based regimens have shown efficacy across all lines of therapy in multiple myeloma (MM), but the agent requires a long intravenous infusion time, lasting...
Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS
Watch our interview with David Sallman, MD.In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual...
Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma
One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar...
Flumatinib Superior to Imatinib in Chronic-Phase Chronic Myeloid Leukemia
Flumatinib, a second-generation tyrosine kinase inhibitor (TKI), led to more molecular responses that were also deeper, compared with imatinib, in patients with newly diagnosed...
